TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

Axogen, Inc. Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2025

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Na
Axogen, Inc. Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2025

Axogen reported preliminary full-year 2025 revenue of approximately $225.2 million, representing 20.2% growth over 2024, with Q4 2025 revenue expected at $59.9 million (21.3% increase). The company achieved FDA Biologics License Application approval for Avance® on December 3, 2025, and expects gross margins above 74%. Cash position improved by approximately $6.0 million to $45.5 million by year-end 2025.

Insights
QCOM   neutral

Mentioned as a recipient of Chinese bank credit lines without specific negative or positive implications


AXGN   positive

Strong revenue growth of 20.2% year-over-year, significant FDA BLA approval milestone for Avance®, improved cash position, gross margins above 74%, and positive momentum across business functions support confidence in strategic execution and future growth prospects.